68266-55-7

Upstream product

• 65784-33-0 methyl 2-(4-hydroxyphenyl)propanoate 
• 938-96-5 2-(4-Hydroxy-phenyl)-propionic acid 
• 859828-48-1 methyl 2-{4-(trifluoromethanesulfonyloxy)phenyl}propanoate 
• 859828-56-1 methyl 2-[4-(cyclohexylmethyl)phenyl]propanoate 

Relevant academic research and scientific papers

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors

The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.

Novel phenylacetic acid derivatives

Phenylacetic acid derivatives of the formula STR1 wherein n is an integer of 2 to 5; STR2 R1 is hydrogen, halogen, trifluoromethyl, nitro or amino; R2 and R3 each independently is hydrogen or lower alkyl; or together form an ethylene group; X1 represents two hydrogen atoms or an oxo group; and Y1 is cyano, hydroxyamidocarbonyl, carbamoyl, 5-tetrazolyl or carboxyl; and for derivatives wherein Y is carboxyl, salts thereof with physiologically compatible bases, esters thereof from physiologically acceptable alcohols and amides thereof from physiologically acceptable amines have valuable pharmacological activity, e.g., as antiinflammatory agents.